One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases

Wesley C. Van Voorhis, Matthew A. Hulverson, Ryan Choi, Wenlin Huang, Samuel L.M. Arnold, Deborah A. Schaefer, Dana P. Betzer, Rama S.R. Vidadala, Sangun Lee, Grant R. Whitman, Lynn K. Barrett, Dustin J. Maly, Michael W. Riggs, Erkang Fan, Thomas J. Kennedy, Saul Tzipori, J. Stone Doggett, Pablo Winzer, Nicoleta Anghel, Dennis ImhofJoachim Müller, Andrew Hemphill, Ignacio Ferre, Roberto Sanchez-Sanchez, Luis Miguel Ortega-Mora, Kayode K. Ojo

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.

Original languageEnglish (US)
Article number109336
JournalVeterinary Parasitology
Volume289
DOIs
StatePublished - Jan 2021

Keywords

  • Antiparastics
  • Apicomplexa
  • Kinase inhibitors

ASJC Scopus subject areas

  • Parasitology
  • veterinary(all)

Fingerprint

Dive into the research topics of 'One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases'. Together they form a unique fingerprint.

Cite this